DE502005006837D1 - Verwendung von Estradiolvalerat in Kombination mit Dienogest zur oralen Therapie der dysfunktionellen uterinen Blutung in Einheit mit einer oralen Kontrazeption - Google Patents

Verwendung von Estradiolvalerat in Kombination mit Dienogest zur oralen Therapie der dysfunktionellen uterinen Blutung in Einheit mit einer oralen Kontrazeption

Info

Publication number
DE502005006837D1
DE502005006837D1 DE502005006837T DE502005006837T DE502005006837D1 DE 502005006837 D1 DE502005006837 D1 DE 502005006837D1 DE 502005006837 T DE502005006837 T DE 502005006837T DE 502005006837 T DE502005006837 T DE 502005006837T DE 502005006837 D1 DE502005006837 D1 DE 502005006837D1
Authority
DE
Germany
Prior art keywords
oral
dienogest
combination
unit
uterine bleeding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE502005006837T
Other languages
German (de)
English (en)
Inventor
Susan Zeun
Pol Boudes
Jan Endrikat
Angelo Secci
Holger Zimmermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35811580&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE502005006837(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Publication of DE502005006837D1 publication Critical patent/DE502005006837D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DE502005006837T 2005-10-13 2005-10-13 Verwendung von Estradiolvalerat in Kombination mit Dienogest zur oralen Therapie der dysfunktionellen uterinen Blutung in Einheit mit einer oralen Kontrazeption Expired - Lifetime DE502005006837D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05022324A EP1787649B1 (de) 2005-10-13 2005-10-13 Verwendung von Estradiolvalerat in Kombination mit Dienogest zur oralen Therapie der dysfunktionellen uterinen Blutung in Einheit mit einer oralen Kontrazeption

Publications (1)

Publication Number Publication Date
DE502005006837D1 true DE502005006837D1 (de) 2009-04-23

Family

ID=35811580

Family Applications (2)

Application Number Title Priority Date Filing Date
DE502005006837T Expired - Lifetime DE502005006837D1 (de) 2005-10-13 2005-10-13 Verwendung von Estradiolvalerat in Kombination mit Dienogest zur oralen Therapie der dysfunktionellen uterinen Blutung in Einheit mit einer oralen Kontrazeption
DE502006008853T Active DE502006008853D1 (de) 2005-10-13 2006-10-12 Verwendung von estradiolvalerat oder estradiol in kombination mit dienogest zur oralen therapie der dysfunktionellen uterinen blutung in einheit mit einer oralen kontrazeption

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE502006008853T Active DE502006008853D1 (de) 2005-10-13 2006-10-12 Verwendung von estradiolvalerat oder estradiol in kombination mit dienogest zur oralen therapie der dysfunktionellen uterinen blutung in einheit mit einer oralen kontrazeption

Country Status (22)

Country Link
EP (2) EP1787649B1 (https=)
JP (2) JP5735200B2 (https=)
KR (2) KR101218872B1 (https=)
CN (1) CN101312733A (https=)
AR (1) AR056694A1 (https=)
AT (2) ATE424828T1 (https=)
CA (1) CA2623024C (https=)
CL (1) CL2011000283A1 (https=)
CY (2) CY1110321T1 (https=)
DE (2) DE502005006837D1 (https=)
DK (2) DK1787649T3 (https=)
DO (1) DOP2006000221A (https=)
ES (2) ES2322479T3 (https=)
HR (1) HRP20090256T1 (https=)
ME (1) ME01056B (https=)
PE (2) PE20100090A1 (https=)
PL (2) PL1787649T3 (https=)
PT (2) PT1787649E (https=)
SI (2) SI1787649T1 (https=)
TW (2) TWI328453B (https=)
UY (1) UY29861A1 (https=)
WO (1) WO2007042296A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004019743B4 (de) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
SI1787649T1 (sl) * 2005-10-13 2009-08-31 Bayer Schering Pharma Ag Uporaba estradiolvalerata v kombinaciji z dienogestom za oralno terapijo disfunkcionalne maternične krvavitve skupaj z oralno kontracepcijo
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4429374C1 (de) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
ATE249222T1 (de) * 1996-07-26 2003-09-15 Wyeth Corp Biphasische orale verhuetungsmethode und kit die eine kombination von progestin und eines oestrogens enthalten
US6251956B1 (en) 1998-08-20 2001-06-26 Ortho Pharmaceutical Corporation Combination progestin oral contraceptive regimen
EP1462106A1 (en) * 2003-03-28 2004-09-29 Pantarhei Bioscience B.V. Pharmaceutical compositions and kits comprising 17-beta-estradiol and a progesteron for the treatment of gynecological disorders
DE102004019743B4 (de) * 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
SI1787649T1 (sl) * 2005-10-13 2009-08-31 Bayer Schering Pharma Ag Uporaba estradiolvalerata v kombinaciji z dienogestom za oralno terapijo disfunkcionalne maternične krvavitve skupaj z oralno kontracepcijo

Also Published As

Publication number Publication date
CA2623024A1 (en) 2007-04-19
EP1933843A1 (de) 2008-06-25
ES2322479T3 (es) 2009-06-22
WO2007042296A1 (de) 2007-04-19
ATE424828T1 (de) 2009-03-15
JP5735200B2 (ja) 2015-06-17
JP2009511526A (ja) 2009-03-19
SI1933843T1 (sl) 2011-06-30
PT1787649E (pt) 2009-05-08
EP1787649A1 (de) 2007-05-23
ES2360302T3 (es) 2011-06-02
CL2011000283A1 (es) 2011-07-08
PT1933843E (pt) 2011-04-29
KR20080065651A (ko) 2008-07-14
HRP20090256T1 (en) 2009-06-30
AR056694A1 (es) 2007-10-17
PL1933843T3 (pl) 2011-06-30
SI1787649T1 (sl) 2009-08-31
CA2623024C (en) 2012-03-06
TW200731977A (en) 2007-09-01
DOP2006000221A (es) 2007-08-31
PE20100090A1 (es) 2010-03-12
CN101312733A (zh) 2008-11-26
DK1787649T3 (da) 2009-06-02
TWI328453B (en) 2010-08-11
UY29861A1 (es) 2007-05-31
DE502006008853D1 (de) 2011-03-17
EP1787649B1 (de) 2009-03-11
TW200829255A (en) 2008-07-16
ATE497387T1 (de) 2011-02-15
CY1111406T1 (el) 2015-08-05
KR20100082389A (ko) 2010-07-16
PL1787649T3 (pl) 2009-08-31
KR101218872B1 (ko) 2013-01-07
CY1110321T1 (el) 2015-01-14
DK1933843T3 (da) 2011-04-18
PE20070555A1 (es) 2007-07-12
JP2013047269A (ja) 2013-03-07
ME01056B (me) 2012-10-20
EP1933843B1 (de) 2011-02-02

Similar Documents

Publication Publication Date Title
IL281111A (en) Preparations for imparting resistance to viral diseases in social insects, and their use
DK1827412T3 (da) Sammensætninger til anvendelse i kirurgi
BRPI0717462A2 (pt) Emprego de valerato de estradiol ou 17 beta- estradiol em combinação com dienogest na terapia oral para manutenção e/ou aumento da libido feminin
BRPI0817866A2 (pt) Instrumento cirúrgico autoalimentado eletricamente com liberação manual
BRPI0813955A2 (pt) composições terapêuticas e o uso das mesmas
BRPI0819575A2 (pt) "bandagens médicas e kit de bandagem médica"
CR9218A (es) Cemento impermeable y composicion sinergica empleada para la obtencion de alta impermeabilidad
IL178458A0 (en) Management of breakthrough bleeding in extended hormonal contraceptive regimens
BRPI0911945A2 (pt) cc10 humana recombinante e suas composições para uso no tratamento de rinite nasal
DK2087890T3 (da) Præparat med vedvarende frigørelse til vævsregenereringsterapi
NO20071297L (no) Farmasøytisk sammenseting omfattende drospirenon og etynylestradiol
IL202351A0 (en) Substituted (oxazolidinon-5-yl-methyl)-2-thiophene-carboxamides and use thereof in the field of blood coagulation
DE502005006837D1 (de) Verwendung von Estradiolvalerat in Kombination mit Dienogest zur oralen Therapie der dysfunktionellen uterinen Blutung in Einheit mit einer oralen Kontrazeption
BRPI0807724A2 (pt) Composição para uso na odontologia
ITMI20041763A1 (it) Nuove formulazioni iniettabili contenenti progesterone
DE602005004879D1 (de) Zahnmedizinischer absorbierender Verband
BRPI0415232A (pt) uso de xenÈnio com hipotermia para tratar asfixia neonatal
NO20055390D0 (no) Thorium-227 for anvendelse i radioterapi pa mykvevssykdommer
CL2003001544A1 (es) Compuestos derivados de 5-cicloalquenil-5h-cromeno[3,4-f]quinolina de formula i, moduladores selectivos del receptor de progesterona; composicion farmaceutica; y su uso en el tratamiento de sangrado uterino disfuncional, dismenorrea, endometriosis, l
TH0601005011A (th) การใช้เอสตราไดออลวาเลอเรตหรือเอสตราไดออลร่วมกับไดอีโนเจสต์สำหรับการรักษาโดยให้ทางปากในการตกเลือดในมดลูกแบบที่ทำงานผิดปกติ ร่วมกับยาคุมกำเนิดสำหรับให้ทางปาก
DE502005001682D1 (de) Medizinisches pflaster zur anwendung auf der haut
CL2003001545A1 (es) Compuestos derivados de 7,9-difluoro-5h-cromeno-[3,4-f]quinolina de formula i, moduladores selectivos del receptor de progesterona; composicion farmaceutica; y su uso en el tratamiento de sangrado uterino disfuncional, dismenorrea, endometriosis, lei
BRPI0908398A2 (pt) Uso de lucantona e antimetabólito em combinação, bm como composição e kit farmacêuticos
CL2007003769A1 (es) Compuestos derivados ciclicos o heterociclicos, moduladores no esteroidales del receptor de progesterona; composicion farmaceutica; y uso para tratar y/o prevenir enfermedades ginecologicas tal como endometriosis y dismenorrea, tumores dependientes d
BRPI0906859A2 (pt) Composições de timol/ácido acético e seu uso no tratamento de onicomicose

Legal Events

Date Code Title Description
8363 Opposition against the patent